Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Elvira Manzano, Roshini Claire Anthony, 2 days ago
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.

Worse outcomes in infiltrating lobular vs ductal carcinoma

06 Sep 2017

Patients with infiltrating lobular carcinoma (ILC) suffer from poorer prognoses compared with those with infiltrating ductal carcinoma (IDC), a new study shows. Moreover, patients with oestrogen receptor-positive (ER+) and progesterone receptor-negative (PR-) tumours have the worst outcomes.

The study included 796,335 breast cancer patients, of which 10.7 percent (n=85,048) had ILC and 89.3 percent (n=711,287) had IDC. Those with squamous cell carcinoma and papillary cystadenocarcinoma histological subtypes and those with mixed diseases were excluded.

Patients in the ILC group tended to have larger tumours (p<0.0001), later stage cancers (p<0.0001), higher percentage of metastatic disease (p<0.0001) and more positive lymph nodes (p<0.0001) compared with those in the IDC group.

Over a median follow-up of 5.5 years, overall survival (OS) for ILC patients was better before 60 months (hazard ratio [HR], 1.118; p<0.0001), while OS beyond 5 years was better for IDC patients (HR, 0.775; p<0.0001).

In terms of disease-specific survival, patients in the IDC group had consistently better outcomes in both the short and long term (HR, 0.809; p<0.0001).

OS and DSS were also significantly better in IDC patients than in ILC patients regardless if they were ER+/PR+ (HR for OS, 0.92; p<0.0001; HR for DSS, 0.66; p<0.0001) or ER+/PR- (HR for OS, 0.81; p<0.0001; HR for DSS, 0.71; p<0.0001).

In both groups, the most common site of metastasis was the bone, with 91.52 percent metastases in the ILC group and 76.04 percent in the IDC group. This was followed by the liver (19.64 percent), lung (13.61 percent) and brain (4.23 percent) in the ILC group, and by the lung (37.11 percent), liver (30.53 percent) and brain (8.24 percent) in the IDC group.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Elvira Manzano, Roshini Claire Anthony, 2 days ago
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.